IOBCF Stock UPDATES ION Beam Application (IOBCF) 15.6000 09/16/2014
Post# of 273256
Posted On: 09/16/2014 2:11:25 PM
ION Beam Application (IOBCF) 15.6000 $IOBCF
IBA Successfully Concludes Litigation Over Competing Fiducial Marker
Marketwire - Tue Aug 06, 5:08AM CDT
IBA (Ion Beam Applications S.A.) (EURONEXT BRUSSELS: IBAB), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, announces the execution of a Letter of Intent to resolve litigation and claims of IBA subsidiary RadioMed Corp. against ONC Solutions, Inc. RadioMed sued ONC for misappropriation of RadioMed's trade secrets and use of them to develop a competing linear fiducial marker called the X-Mark(TM).
COMPASS Provides Needed Flexibility for Optimal QA Efficiency Enabling Measurement -- as Well as Full 3D Calculation-Based Independent Treatment Plan Verification
Marketwire - Thu Aug 01, 5:34AM CDT
IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, announces the launch of a milestone: COMPASS 3.0 plan verification system. COMPASS, the first patient anatomy- centric and most sophisticated solution for advanced IMRT and rotational plan verification now provides a new two-in-one solution: calculation-based full 3D independent Treatment Plan System (TPS) verification and measurement-based Quality Assurance (QA) for the complete treatment chain, including linear accelerators. COMPASS offers superior full workflow flexibility, allowing physicists and dosimetrists to choose the most efficient QA for any clinical need. This announcement will be made at the 55th American Association of Physicists in Medicine Annual Meeting and Exhibition, Booth 1035.
IBA Successfully Concludes Litigation Over Competing Fiducial Marker
Marketwire - Tue Aug 06, 5:08AM CDT
IBA (Ion Beam Applications S.A.) (EURONEXT BRUSSELS: IBAB), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, announces the execution of a Letter of Intent to resolve litigation and claims of IBA subsidiary RadioMed Corp. against ONC Solutions, Inc. RadioMed sued ONC for misappropriation of RadioMed's trade secrets and use of them to develop a competing linear fiducial marker called the X-Mark(TM).
COMPASS Provides Needed Flexibility for Optimal QA Efficiency Enabling Measurement -- as Well as Full 3D Calculation-Based Independent Treatment Plan Verification
Marketwire - Thu Aug 01, 5:34AM CDT
IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, announces the launch of a milestone: COMPASS 3.0 plan verification system. COMPASS, the first patient anatomy- centric and most sophisticated solution for advanced IMRT and rotational plan verification now provides a new two-in-one solution: calculation-based full 3D independent Treatment Plan System (TPS) verification and measurement-based Quality Assurance (QA) for the complete treatment chain, including linear accelerators. COMPASS offers superior full workflow flexibility, allowing physicists and dosimetrists to choose the most efficient QA for any clinical need. This announcement will be made at the 55th American Association of Physicists in Medicine Annual Meeting and Exhibition, Booth 1035.
(0)
(0)Scroll down for more posts ▼